160 related articles for article (PubMed ID: 10563640)
21. Backbone and side-chain 1H, 15N and 13C resonance assignments of S18Y mutant of ubiquitin carboxy-terminal hydrolase L1.
Tse HS; Hu HY; Sze KH
Biomol NMR Assign; 2011 Oct; 5(2):165-8. PubMed ID: 21298373
[TBL] [Abstract][Full Text] [Related]
22. UCH-L1 S18Y variant and risk of Parkinson's disease in Asian populations: an updated meta-analysis.
Zhu R; Zhu Y; Liu X; He Z
Neurodegener Dis; 2014; 14(4):194-203. PubMed ID: 25471998
[TBL] [Abstract][Full Text] [Related]
23. Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy.
Kabuta T; Wada K
Autophagy; 2008 Aug; 4(6):827-9. PubMed ID: 18635949
[TBL] [Abstract][Full Text] [Related]
24. Complex interactions in Parkinson's disease: a two-phased approach.
Maraganore DM; de Andrade M; Lesnick TG; Farrer MJ; Bower JH; Hardy JA; Rocca WA
Mov Disord; 2003 Jun; 18(6):631-6. PubMed ID: 12784265
[TBL] [Abstract][Full Text] [Related]
25. Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age.
Liu Y; Chen YY; Liu H; Yao CJ; Zhu XX; Chen DJ; Yang J; Lu YJ; Cao JY
Neurol Sci; 2015 Feb; 36(2):179-88. PubMed ID: 25370916
[TBL] [Abstract][Full Text] [Related]
26. [Association of the ubiquitin carboxy-terminal hydrolase-L1 genetic polymorphism with the susceptibility of Parkinson's disease].
Xiao Y; Zhang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):586-7. PubMed ID: 18841579
[TBL] [Abstract][Full Text] [Related]
27. Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson's disease in a Han-Chinese population.
Zhang ZJ; Burgunder JM; An XK; Wu Y; Chen WJ; Zhang JH; Wang YC; Xu YM; Gou YR; Yuan GG; Mao XY; Peng R
Neurosci Lett; 2008 Sep; 442(3):200-2. PubMed ID: 18638528
[TBL] [Abstract][Full Text] [Related]
28. The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells.
Kyratzi E; Pavlaki M; Stefanis L
Hum Mol Genet; 2008 Jul; 17(14):2160-71. PubMed ID: 18411255
[TBL] [Abstract][Full Text] [Related]
29. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
30. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
Solano SM; Miller DW; Augood SJ; Young AB; Penney JB
Ann Neurol; 2000 Feb; 47(2):201-10. PubMed ID: 10665491
[TBL] [Abstract][Full Text] [Related]
31. UCHL1 is a Parkinson's disease susceptibility gene.
Maraganore DM; Lesnick TG; Elbaz A; Chartier-Harlin MC; Gasser T; Krüger R; Hattori N; Mellick GD; Quattrone A; Satoh J; Toda T; Wang J; Ioannidis JP; de Andrade M; Rocca WA;
Ann Neurol; 2004 Apr; 55(4):512-21. PubMed ID: 15048890
[TBL] [Abstract][Full Text] [Related]
32. Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1.
Konya C; Hatanaka Y; Fujiwara Y; Uchida K; Nagai Y; Wada K; Kabuta T
Neurochem Int; 2011 Aug; 59(2):251-8. PubMed ID: 21693148
[TBL] [Abstract][Full Text] [Related]
33. The effect of Parkinson's-disease-associated mutations on the deubiquitinating enzyme UCH-L1.
Andersson FI; Werrell EF; McMorran L; Crone WJ; Das C; Hsu ST; Jackson SE
J Mol Biol; 2011 Mar; 407(2):261-72. PubMed ID: 21251915
[TBL] [Abstract][Full Text] [Related]
34. Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.
Xilouri M; Kyratzi E; Pitychoutis PM; Papadopoulou-Daifoti Z; Perier C; Vila M; Maniati M; Ulusoy A; Kirik D; Park DS; Wada K; Stefanis L
Hum Mol Genet; 2012 Feb; 21(4):874-89. PubMed ID: 22076440
[TBL] [Abstract][Full Text] [Related]
35. UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study.
Facheris M; Strain KJ; Lesnick TG; de Andrade M; Bower JH; Ahlskog JE; Cunningham JM; Lincoln S; Farrer MJ; Rocca WA; Maraganore DM
Neurosci Lett; 2005 Jun 10-17; 381(1-2):131-4. PubMed ID: 15882803
[TBL] [Abstract][Full Text] [Related]
36. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.
Kabuta T; Setsuie R; Mitsui T; Kinugawa A; Sakurai M; Aoki S; Uchida K; Wada K
Hum Mol Genet; 2008 May; 17(10):1482-96. PubMed ID: 18250096
[TBL] [Abstract][Full Text] [Related]
37. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
38. Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.
Hutter CM; Samii A; Factor SA; Nutt JG; Higgins DS; Bird TD; Griffith A; Roberts JW; Leis BC; Montimurro JS; Kay DM; Edwards KL; Payami H; Zabetian CP
Eur J Neurol; 2008 Feb; 15(2):134-9. PubMed ID: 18093156
[TBL] [Abstract][Full Text] [Related]
39. The functions of UCH-L1 and its relation to neurodegenerative diseases.
Setsuie R; Wada K
Neurochem Int; 2007; 51(2-4):105-11. PubMed ID: 17586089
[TBL] [Abstract][Full Text] [Related]
40. Characterization of multimetric variants of ubiquitin carboxyl-terminal hydrolase L1 in water by small-angle neutron scattering.
Naito S; Mochizuki H; Yasuda T; Mizuno Y; Furusaka M; Ikeda S; Adachi T; Shimizu HM; Suzuki J; Fujiwara S; Okada T; Nishikawa K; Aoki S; Wada K
Biochem Biophys Res Commun; 2006 Jan; 339(2):717-25. PubMed ID: 16316632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
